| ID | 1172 |
| Name of the vaccine | rBV A/B |
| Microbe | Bacteria |
| Disease name | Botulism |
| Name of bacteria | Clostridium botulinum |
| Type of vaccine | Recombinant |
| Nucleic acid content | DNA |
| Age | 18 to 55 years |
| Description of the vaccine | Recombinant Botulinum vaccine A/B. |
| Name of the manufacturer | DynPort Vaccine Company LLC, A GDIT Company |
| Name of the manufacturing country | NA |
| Year of manufacture | 2019 |
| Clinical Phase status | Clinical - Withdrawn |
| Bacterial strain | Gram-positive anaerobic bacteria. |
| Efficacy | NA |
| Vaccine formulation | Suspension for injection |
| Dosage | 0.5 mL dose at Days 0, 28 and 182. |
| Mechanism of action | BoNT neutralizing antibodies bind to BoNT and prevent its action at the cholinergic neurons. |
| Route of administration | Intramuscular |
| Indications | Protects from BoNT serotype A, subtype A1 (BoNT/A1) and BoNT serotype B, subtype B1 (BoNT/B1). |
| Export | NA |
| Approval | NA |
| Adjuvant | NA |
| Repurposing | NA |
| Side effects of vaccine | Transient mild inflammation at the injection site. |
| Post vaccination | NA |
| Dose type | Combination doses |
| Interspecies transfer | NA |
| PubMed identifier | 22269871 |
| Clinical trial number | NCT01940315 |
| Reference | NA |
| Other name | NA |
| Additional Links | NA
|